Diabetic peripheral neuropathy therapy advances after a long quiet period
Capsaicin patch maturity, novel sodium channel modulators, and emerging disease-modifying programs are reshaping diabetic peripheral neuropathy management.
Diabetic peripheral neuropathy has been a duloxetine-pregabalin-gabapentin category for years with limited progress. High-concentration capsaicin patch use is established, novel sodium channel modulators (Nav1.7 and Nav1.8) are in late-stage trials, and aldose reductase inhibitor programs targeting underlying biology are reading out. The diagnostic-pathway question matters; DPN is often clinically obvious but rarely systematically assessed in the primary-care diabetes visit.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is spasticity?
- SnapshotDementia subtype therapy reference (2026)
- ExplainedAcute ischemic stroke explained